Foresite Capital Management V, LLC
Follow13F filer, CIK 1792206, West Hollywood, CA
Foresite Capital Management V, LLC reported $289,147,716 across 9 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16.
Accepted , ingested 13F-HR 0001104659-26-128380
- Period
- 2026-09-30
- Reported value
- $289M
- Holdings
- 9
- Top 10 weight
- 100%
- New
- 1
- Sold out
- 1
Part of the filer group Foresite Capital Management VI LLC
Foresite Capital Management IV, LLCForesite Capital Management VI LLC
- Foresite Capital Management IV, LLC
- Foresite Capital Management VI LLC
- Foresite Public & Crossover Opportunities Fund I, L.P.
- Foresite Public & Crossover Opportunities Management I, LLC
- James B. Tananbaum
- Foresite Capital Fund VI LP
Stakes and trades reported after 2026-09-30
13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.
- IRLA QUINCE THERAPEUTICS INC: 13G 652,039 shares, 6% of the class, 13G filed 2026-10-14, 0001104659-26-115859Timeline
Accepted , ingested
Largest buys vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| LTGOnew | +3,562,984 | $59.5M |
| NRIXadded | +193,742 | $4.59M |
| HIMSadded | +145,600 | $4.34M |
| ODTXadded | +16,497 | $367K |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| LYELexited | -476,386 | -$6.69M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q3 2026
Share positions as resolved from 13F-HR 0001104659-26-128380, largest first. % of portfolio is the value over $289,147,716, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| CGONCG ONCOLOGY INC | 1,079,050 | $76.5M | 26.45% | 0 | Timeline | ||
| LTGOLATIGO BIOTHERAPEUTICS INC | 3,562,984 | $59.5M | 20.58% | new | Timeline | ||
| ALMSALUMIS INC | 5,896,995 | $43.6M | 15.07% | 0 | Timeline | ||
| HIMSHIMS & HERS HEALTH INC | 883,751 | $26.3M | 9.11% | +145,600 | Timeline | ||
| IRONDISC MEDICINE INC | 374,069 | $24.5M | 8.47% | 0 | Timeline | ||
| PHVSPHARVARIS N V | 664,142 | $21.1M | 7.29% | 0 | Timeline | ||
| ODTXODYSSEY THERAPEUTICS INC | 729,602 | $16.2M | 5.61% | +16,497 | Timeline | ||
| NRIXNURIX THERAPEUTICS INC | 458,742 | $10.9M | 3.76% | +193,742 | Timeline | ||
| EIKNEIKON THERAPEUTICS INC | 1,318,983 | $10.6M | 3.67% | 0 | Timeline |
Sold out in Q3 2026
Positions in the previous quarter's report that this quarter's report no longer lists.
| Security | Shares before | Value before | Type |
|---|---|---|---|
| LYELLYELL IMMUNOPHARMA INC | 476,386 | $6.69M | shares |
How Q3 2026 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0001104659-26-128380 | base | 2026-11-16 |